A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints

There is growing interest in integrated Phase I/II oncology clinical trials involving molecularly targeted agents (MTA). One of the main challenges of these trials are nontrivial dose–efficacy relationships and administration of MTAs in combination with other agents. While some designs were recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Mozgunov, Pavel, Jaki, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899762/
https://www.ncbi.nlm.nih.gov/pubmed/31298770
http://dx.doi.org/10.1002/bimj.201800313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899762/
https://www.ncbi.nlm.nih.gov/pubmed/31298770
http://dx.doi.org/10.1002/bimj.201800313

Ejemplares similares